GlassScriptPhysician profile
Alison Pelletier
NPI 1023619699
$2,447.27
in general payments reported to CMS, 2019-2025
18 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.48 · 2023: $231 · 2024: $381 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $526.09 | 2024-2025 | Caplyta |
| Abbvie INC. | $457.16 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $324.44 | 2025 | Jornay Pm |
| Corium, LLC | $175.54 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $152.96 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $142.03 | 2024-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $124.14 | 2023-2024 | Jornay Pm |
| Lundbeck LLC | $123.46 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $115.60 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $83.88 | 2021-2025 | Bexsero |
| Neurocrine Biosciences, INC. | $53.30 | 2025 | |
| Pfizer INC. | $44.17 | 2023-2025 | |
| Exeltis, USA INC. | $30.28 | 2024 | Slynd |
| Kaleo, INC. | $23.67 | 2024 | Auvi-Q |
| Organon LLC | $21.13 | 2025 | Nexplanon |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.35 | 2023 | Flumist Quadrivalent |
| Alkermes, INC. | $16.18 | 2025 | Aristada, Lybalvi |
| Merck Sharp & Dohme LLC | $13.89 | 2023 | Gardasil 9, Vaxneuvance, Vaxelis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Pelletier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.